| pubmed-article:1831826 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1831826 | lifeskim:mentions | umls-concept:C1709854 | lld:lifeskim |
| pubmed-article:1831826 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:1831826 | lifeskim:mentions | umls-concept:C0376152 | lld:lifeskim |
| pubmed-article:1831826 | lifeskim:mentions | umls-concept:C0301944 | lld:lifeskim |
| pubmed-article:1831826 | lifeskim:mentions | umls-concept:C0003250 | lld:lifeskim |
| pubmed-article:1831826 | lifeskim:mentions | umls-concept:C0021084 | lld:lifeskim |
| pubmed-article:1831826 | lifeskim:mentions | umls-concept:C0033414 | lld:lifeskim |
| pubmed-article:1831826 | lifeskim:mentions | umls-concept:C1515655 | lld:lifeskim |
| pubmed-article:1831826 | lifeskim:mentions | umls-concept:C1515895 | lld:lifeskim |
| pubmed-article:1831826 | lifeskim:mentions | umls-concept:C0591833 | lld:lifeskim |
| pubmed-article:1831826 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:1831826 | pubmed:dateCreated | 1991-9-27 | lld:pubmed |
| pubmed-article:1831826 | pubmed:abstractText | The role of host anti-donor cells in rejection of fully allogeneic donor T cell-depleted marrow was investigated by using mAb or immunotoxins directed against T cell or NK cell determinants. Immunotoxins consisting of mAb conjugated to a low oligosaccharide-containing fraction of purified ricin toxin A chain (RTA) facilitated in vivo-depletion of target cell populations. BALB/c and DBA/1 donors were selected based upon their expression (BALB/c) or lack of (DBA/1) hemopoietic histocompatibility (Hh1) Ag, which may serve as targets for donor rejection in C57BL/6 hosts. When studies directed toward eliminating CD3+ cells were performed in both systems, injections of intact anti-CD3 mAb or anti-CD3-RTA reproducibly produced the highest engraftment values. The fact that engraftment values obtained with anti-CD3 or anti-CD3-RTA therapy in allogeneic systems were substantially higher than in syngeneic controls suggested that engraftment stimulatory proteins were released upon TCR engagement. Elevated levels of cytokines and a high mortality rate in allogeneic recipients confirmed that this was the case. Nonstimulatory preparations of anti-CD3F(ab')2 fragments and anti-CD3F(ab')2-RTA promoted engraftment of both types of allogeneic marrow, as measured by short term 125I-IUdR assays, suggesting that stimulation was not a prerequisite for engraftment. Recipients of anti-CD3F(ab')2 or anti-CD3F(ab')2-RTA showed a marked reduction of host CD3+ cells as measured by immunofluorescence and flow cytometry. In long term chimerism studies, recipients of Hh1-disparate marrow and anti-CD3F(ab')2 had a dramatic increase in donor cell engraftment as compared to controls, indicating that positive effects on engraftment were long lived. Studies further showed that BALB/c donor cells exhibiting an Hh1 disparity were rejected by host cells expressing NK1.1 or Ly-1 (NK cells and T cells). In contrast, DBA/1 donor cells that were not Hh1-disparate were rejected by cells expressing Ly-1, but not NK1.1 (T cells only). These studies provide definitive data that CD3+ cells participate in the rejection of either Hh1+ or Hh1null T cell-depleted allografts and offer new strategies for alloengraftment using regimens containing nonmitogenic anti-CD3. | lld:pubmed |
| pubmed-article:1831826 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1831826 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1831826 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1831826 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1831826 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1831826 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:1831826 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1831826 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1831826 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1831826 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1831826 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1831826 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1831826 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1831826 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1831826 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1831826 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:1831826 | pubmed:issn | 0022-1767 | lld:pubmed |
| pubmed-article:1831826 | pubmed:author | pubmed-author:CarrollS FSF | lld:pubmed |
| pubmed-article:1831826 | pubmed:author | pubmed-author:GressR ERE | lld:pubmed |
| pubmed-article:1831826 | pubmed:author | pubmed-author:ValleraD ADA | lld:pubmed |
| pubmed-article:1831826 | pubmed:author | pubmed-author:HirschRR | lld:pubmed |
| pubmed-article:1831826 | pubmed:author | pubmed-author:BlazarB RBR | lld:pubmed |
| pubmed-article:1831826 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1831826 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:1831826 | pubmed:volume | 147 | lld:pubmed |
| pubmed-article:1831826 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1831826 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1831826 | pubmed:pagination | 1492-503 | lld:pubmed |
| pubmed-article:1831826 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:1831826 | pubmed:meshHeading | pubmed-meshheading:1831826-... | lld:pubmed |
| pubmed-article:1831826 | pubmed:meshHeading | pubmed-meshheading:1831826-... | lld:pubmed |
| pubmed-article:1831826 | pubmed:meshHeading | pubmed-meshheading:1831826-... | lld:pubmed |
| pubmed-article:1831826 | pubmed:meshHeading | pubmed-meshheading:1831826-... | lld:pubmed |
| pubmed-article:1831826 | pubmed:meshHeading | pubmed-meshheading:1831826-... | lld:pubmed |
| pubmed-article:1831826 | pubmed:meshHeading | pubmed-meshheading:1831826-... | lld:pubmed |
| pubmed-article:1831826 | pubmed:meshHeading | pubmed-meshheading:1831826-... | lld:pubmed |
| pubmed-article:1831826 | pubmed:meshHeading | pubmed-meshheading:1831826-... | lld:pubmed |
| pubmed-article:1831826 | pubmed:meshHeading | pubmed-meshheading:1831826-... | lld:pubmed |
| pubmed-article:1831826 | pubmed:meshHeading | pubmed-meshheading:1831826-... | lld:pubmed |
| pubmed-article:1831826 | pubmed:meshHeading | pubmed-meshheading:1831826-... | lld:pubmed |
| pubmed-article:1831826 | pubmed:meshHeading | pubmed-meshheading:1831826-... | lld:pubmed |
| pubmed-article:1831826 | pubmed:meshHeading | pubmed-meshheading:1831826-... | lld:pubmed |
| pubmed-article:1831826 | pubmed:meshHeading | pubmed-meshheading:1831826-... | lld:pubmed |
| pubmed-article:1831826 | pubmed:meshHeading | pubmed-meshheading:1831826-... | lld:pubmed |
| pubmed-article:1831826 | pubmed:meshHeading | pubmed-meshheading:1831826-... | lld:pubmed |
| pubmed-article:1831826 | pubmed:meshHeading | pubmed-meshheading:1831826-... | lld:pubmed |
| pubmed-article:1831826 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1831826 | pubmed:articleTitle | In vivo administration of anti-CD3 monoclonal antibodies or immunotoxins in murine recipients of allogeneic T cell-depleted marrow for the promotion of engraftment. | lld:pubmed |
| pubmed-article:1831826 | pubmed:affiliation | Department of Pediatrics, University of Minnesota Hospital and Clinic, Minneapolis 55455. | lld:pubmed |
| pubmed-article:1831826 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1831826 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:1831826 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1831826 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1831826 | lld:pubmed |
